Nityr (Nitisinone) Patent Expiration, LOE Window & CMS Spending
Nityr (Nitisinone) by Cycle: FDA Orange Book LOE 2035-01-05, 3 AB generics, $20.0M 2024 CMS Part D & Medicaid spend, and $89,106 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Cycle |
| FDA Application & Pathway | N209449 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2035-01-05 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $20.0M |
| 2024 Medicare Part D Spend | $41K |
| 2024 Medicaid Spend | $20.0M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($89,106 intro WAC) |